Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis.

ABSTRACT:

Objectives

Recently, NRG-GY018 clinical trial demonstrated that adding pembrolizumab to chemotherapy led to significantly longer progression-free survival than chemotherapy alone in the first-line treatment of advanced or recurrent endometrial cancer (a/rEC). This analysis aimed to estimate the cost-effectiveness of pembrolizumab plus paclitaxel plus carboplatin chemotherapy (PC) as the first-line treatment for a/rEC in the US and China.

Methods

A Markov model based on the clinical data from NRG-GY018 trial was established to estimate the cost and efficacy of PC and paclitaxel plus carboplatin groups for a/rEC in mismatch repair-proficient (pMMR) and mismatch repair-deficient (dMMR) populations. Direct medical costs and utility values were collected from the government datab

SUBMITTER: Zhao X 

PROVIDER: S-EPMC12164117 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature